In this study, our objective was to evaluate aldosterone levels after administration of furosemide and angiotensin-converting enzyme (ACE) 
Introduction
The association between obesity and hypertension was recognised and described almost a century ago, but mechanisms that underlie this connection are still not fully understood. Vasoconstriction and sodium retantion seem to be the cornerstones of obesity-hypertension puzzle. However, pathways that possibly lead to vasoconstriction and sodium retention are numerous. It has been shown that hyperleptinaemia, hyperinsulinaemia and elevated free fatty acids may induce sympathetic activation and vasoconstriction.
The renin-angiotensin aldosterone system (RAAS) seems to be activated in obesity despite a state of volume expansion and sodium retention. There is a positive correlation between body weight and plasma aldosterone to plasma renin activity ratio (3, 4, 6) . In some studies, elevated serum aldosterone levels have been reported in obese individuals (3) (4) (5) (6) (7) (8) (9) (10) . Aldosterone can be elevated in obese hypertensive individuals, whereas renin usually stays within normal levels (2, 22, 24) . In addition, obese subjects who lost weight had lower aldosterone levels (7) . Obese individuals show an exaggerated aldosterone increase after furosemide administration (2, 8) .
In this study, our objective was to evaluate aldosterone levels after furosemide and angiotensin-converting enzyme inhibiting drug administration in hypertensive and normotensive obese women.
Materials and Methods
Eighty obese women, fourty normotensive (group I) (mean age 45.30±6.10 year) and fourty hypertensive (group II) (mean age 44.70±5.20 year), ranging from 35 to 60 (mean 25±5) years old were included in the study. Anthropometric variables included body mass index (BMI) (calculated as weight (kg) divided by height (m 2 )), WHR, waist, and waist/height. Waist and hip circumferences were measured with an anthropometric tape to the nearest centimeter with the subject standing. Waist circumference was taken at the level of the umbili-cus and hip circumference was taken at the level of the maximum protrusion of the gluteal muscles.
Mean body mass index (BMI) was 34.06±1.70 kg/m 2 in Group I and 33.70±3.73 kg/m 2 in Group II. In group I, mean systolic and diastolic blood pressures were 104.110 ± 24.50 mmHg, 60.30 ± 6.70 mmHg, respectively. In group II, mean systolic blood pressure was 165.60±20.9 mmHg and mean diastolic blood pressure was 110.75 ± 11.7 mmHg. These findings were statistically significantly different (p<0.05).
Exclusion criterion were dyslipidemia, diabetes mellitus, hyperthyroidism, hypothyroidism, use of antihypertensive or oral contraseptive drugs at the time of study. Pregnancy or risk of pregnancy were also among the exclusion criteria. The subjects in the study gave informed consent. No significant difference was observed between two groups regarding anthropometric data ( Table 1) .
Aldosterone tests were performed on blood samples. Patients received a normal sodium diet (approximately 3 g/day) for at least two weeks before either test. Drugs that alter sodium, potassium, and fluid balance (diuretics, antihypertensives, steroids, oral contraceptives) were discontinued. Renin inhibitors (e.g, propranolol) were not be taken at least one week before the test. Blood was drawn while subjects rested supine for 30 to 90 minutes. Plasma aldosterone was measured with a radioimmunoassay. In healthy supine subjects, aldosterone levels averaged from 1 to 16 ng/dl in our laboratories. Insulin sensitivity was measured by HOMA.
Plasma aldosterone measurements were possessed from the blood taken from the forehand of the patients at 08.30 am after resting two hours at supine position. According to the measurement technique, plasma aldosterone levels were measured from 1 to 16 ng/dl. There was no salt restriction for any of the patients for three days. At the first day, 40 mg furosemide was administered to all patients after blood was drawn for basal aldosterone levels and then at the twentieth minute, there was another blood drawal for aldosterone levels. One week later, same patients were given 25 mg sublingual captopril after blood was drawn for basal aldosterone measurement and then at the twentieth minute, there was another blood drawal for aldosterone levels. The anthropometric measurements (Table 1 ) and chemical analyses ( Table 2) were assessed by mean test. Insulin and aldosterone was measured by means of radioimmunoassay. Results are expressed as mean ± SD. All variables were compared by 2 sample t-Test. Significance level was defined at p<0.05.
Results and Discussion
Baseline aldosteron levels of hypertensive obese patients (group II) were higher than baseline aldosteron levels of normotensive obese patients (group I). Mean plasma aldosterone level was measured as 9.45±2.60 ng/dl before administration of furosemide. It changed to 8.85±2.70 ng/dl after administration of furosemide in group I. In the same group, mean aldosterone level was first 9.175±2.89 ng/dl, and 8.75±2.70 ng/dl after captoprile.
Mean plasma aldosterone level was After furosemide administration to hypertensive obese patients, aldosterone levels decreased more than that of the captoprile administration. The decrease of aldosterone levels by angiotensin-converting enzyme inhibitors was less at the hypertansive obese patients.
Conclussions
Obesity and hypertension have reached epidemic proportions in the modern world. The pathophysiological consequences of both conditions are serious and numerous, mainly affecting the cardiovascular system. Evidence that obesity is a major cause of hypertension also comes from multiple studies showing that most hypertensive patients are overweight (11) (12) (13) (14) (15) (16) (17) (18) (19) . Results from the Framingham Heart Study, for example, suggest that approximately 65% to 75% of the risk for hypertension can be directly attributed to excess weight (12) .
There are several potential mechanisms that could mediate hypertension associated with obesity, (a) increased renal sympathetic activity (4, 7, 11), (b) activation of renin-angiotensin sysem, (2, 3, 4, 10, 11) and, (c) altered intrarenal physical forces (4, 11, 13), (d) hyperinsulinemia, have also been suggested to raise arterial pressure in obese subjects (4, 10, 11 16) . Recently, hyperactivity of the renin-aldosterone system (RAAS) has been described in many studies (2, 7, 8-10, 20-22, 23) . Elevated se-rum aldosterone levels have been reported in obese individuals, and it is postulated that a yet unidentified factor (possibly a fatty acid) derived from adipose tissue causes the release of a hepatic factor that in turn steps up aldosterone synthesis (8) .
Maxwell et al. have compared plasma norepinephrine, renin activity, aldosterone, and insulin levels between normotensive and hypertensive obese subjects. Mean values for baseline insuline and plasma norepinephrine were elevated in obese subjects compared to nonobese controls. However, when normotensive and hypertensive groups were compared, mean values for renin activity and aldosterone were not different (16) . On the other hand, Goodfriend et al. have shown a relationship between aldosterone and insulin concentrations in obesity. In addition, they also suggested a relationship between plasma aldosterone concentrations and systolic blood pressure in obese subjects. Aldosterone and insulin concentrations were higher in obese hypertensive patients. These findings have suggested that insulin can have a role in hypertension in obese subjects through renin-aldosterone system (23).
Rocchini et al. determined the role of aldosterone in the regulation of blood pressure in obese adolescents. The obese adolescents had significantly higher supine and 2-hour upright plasma aldosterone concentrations (17 +/-8 vs 6 +/-2 ng/dl and 30 +/-11 vs 14 +/-8 ng/dl (25) . In another study, plasma aldosterone levels in obese women correlated directly with visceral adipose tissue and inversely with insulin sensitivity. The results were not the same in men. These findings were independent of plasma renin activity (6) .
In our study, normotensive or hypertensive obese subjects had same fasting insulin levels. On the other hand, hypertensive obese patients had higher postprandial insulin levels than normotensive patients. Postprandial hyperinsulinemia might be significant for aldosterone synthesis. Mean aldosterone levels at the supine position were normal in our two groups. Despite the normal range of aldosteron levels at baseline level, hypertensive obese patients had higher plasma levels than obese patients without hypertension. Indeed, in hypertensive obese patients after furosemide administration, aldosterone levels decreased more than that of the captoprile administration.
